Continuous Complete Hematological and Cytogenetic Remission with Molecular Minimal Residual Disease 9 Years after Discontinuation of Interferon-α in a Patient with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia

Publisher： Karger

E-ISSN： 1421-9662|115|1-2|109-112

ISSN： 0001-5792

Source： Acta Haematologica, Vol.115, Iss.1-2, 2006-01, pp. : 109-112

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome‐positive acute lymphoblastic leukemia

By  

CANCER, Vol. 120, Iss. 10, 2014-05 ,pp. : 1514-1519

John Wiley & Sons Inc

Access to resources Recommend Favorite

Long-Term Outcomes after Imatinib Mesylate Discontinuation in Chronic Myeloid Leukemia Patients with Undetectable Minimal Residual Disease

By  

Acta Haematologica, Vol. 135, Iss. 3, 2015-11 ,pp. : 133-139

Karger

Access to resources Recommend Favorite

Long‐term patient‐reported outcomes from an open‐label safety and efficacy study of bosutinib in Philadelphia chromosome–positive chronic myeloid leukemia patients resistant or intolerant to prior therapy

By  

CANCER, Vol. 124, Iss. 3, 2018-02 ,pp. : 587-595

John Wiley & Sons Inc

Access to resources Recommend Favorite

Philadelphia-Positive Chronic-Phase Chronic Myeloid Leukaemia after Long-Term Remission of Philadelphia-Negative Acute Lymphoblastic Leukaemia

By  

Acta Haematologica, Vol. 119, Iss. 2, 2008-04 ,pp. : 124-125

Karger

Access to resources Recommend Favorite

Pre-Emptive Treatment with Nilotinib after Second Allogeneic Transplantation in a Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patient with High Risk of Relapse

By  

Acta Haematologica, Vol. 123, Iss. 4, 2010-05 ,pp. : 242-247

Karger

Access to resources Recommend Favorite